[go: up one dir, main page]

MA45690A - Anticorps anti-tgfb, méthodes et utilisations - Google Patents

Anticorps anti-tgfb, méthodes et utilisations

Info

Publication number
MA45690A
MA45690A MA045690A MA45690A MA45690A MA 45690 A MA45690 A MA 45690A MA 045690 A MA045690 A MA 045690A MA 45690 A MA45690 A MA 45690A MA 45690 A MA45690 A MA 45690A
Authority
MA
Morocco
Prior art keywords
methods
tgfb antibodies
tgfb
antibodies
Prior art date
Application number
MA045690A
Other languages
English (en)
Inventor
Gregory J Carven
Thomas Schurpf
Katherine Turner
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA45690A publication Critical patent/MA45690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045690A 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations MA45690A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US201662371355P 2016-08-05 2016-08-05

Publications (1)

Publication Number Publication Date
MA45690A true MA45690A (fr) 2019-05-22

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045690A MA45690A (fr) 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations

Country Status (13)

Country Link
US (2) US20190292254A1 (fr)
EP (1) EP3484499A4 (fr)
JP (2) JP7128801B2 (fr)
KR (1) KR102577551B1 (fr)
CN (1) CN110049773A (fr)
AU (1) AU2017294772B2 (fr)
BR (1) BR112019000621A2 (fr)
CA (1) CA3030862A1 (fr)
IL (1) IL264161B1 (fr)
MA (1) MA45690A (fr)
MX (1) MX2019000514A (fr)
SG (1) SG11201900200XA (fr)
WO (1) WO2018013939A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002199B8 (pt) 2013-08-01 2024-03-05 Argen X N V Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
KR20180122397A (ko) 2016-03-11 2018-11-12 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
EP3820896A1 (fr) * 2018-07-11 2021-05-19 Scholar Rock, Inc. INHIBITEURS DE TGFbeta1 ET LEUR UTILISATION
HRP20212034T1 (hr) 2018-07-11 2022-04-01 Scholar Rock, Inc. Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
BR112021000353A2 (pt) 2018-07-11 2021-08-03 Scholar Rock, Inc. inibidores de tgfb1 de alta afinidade, isoforma-seletivos, e seus usos
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
BR112021015056A2 (pt) 2019-01-30 2022-01-11 Scholar Rock Inc Inibidores específicos de complexos ltbp de tgf-beta e usos dos mesmos
WO2021079958A1 (fr) * 2019-10-25 2021-04-29 第一三共株式会社 Combinaison d'anticorps anti-garp et d'immunorégulateur
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
WO2022256723A2 (fr) 2021-06-03 2022-12-08 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
WO2023288277A1 (fr) 2021-07-14 2023-01-19 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgfb1 et leurs utilisations
CA3230246A1 (fr) * 2021-09-30 2023-04-06 Wenxin Xu Anticorps bispecifique et son application
WO2024149237A1 (fr) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 Molécule de liaison au tgfβ1, molécule de liaison garp-tgfβ1 et leur utilisation médicale
WO2024164807A1 (fr) * 2023-02-06 2024-08-15 贝达药业股份有限公司 Anticorps multispécifique et son utilisation
WO2024187051A1 (fr) 2023-03-07 2024-09-12 Scholar Rock, Inc. Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002641A1 (fr) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
CA2595610C (fr) * 2004-12-21 2013-03-05 Astrazeneca Ab Anticorps diriges contre l'angiopoietine 2 et leurs utilisations
EP2468881A3 (fr) * 2005-07-21 2012-08-15 Abbott Laboratories Expression de gènes multiples incluant des constructions molles avec des polyprotéines, des pro-polyprotéines et protéolyse
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2573175B1 (fr) * 2010-05-18 2020-07-08 Medical and Biological Laboratories Co., Ltd. ANTICORPS POUVANT SE LIER AU FACTEUR DE CROISSANCE TRANSFORMANT ALPHA ET PRÉSENTANT UNE ACTIVITÉ ANTIPROLIFÉRATIVE SUR LE CANCER À MUTATION DE GÈNE Ras
EP3263601B1 (fr) * 2012-10-02 2021-11-24 Bristol-Myers Squibb Company Combinaison d'anticorps anti-kir et anti-pd-1 pour traiter le cancer
SG10201913751RA (en) * 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
BR112016002199B8 (pt) * 2013-08-01 2024-03-05 Argen X N V Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
WO2015171691A2 (fr) * 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions et procédés de modulation de facteur de croissance
WO2016164468A2 (fr) * 2015-04-07 2016-10-13 The Trustees Of The University Of Pennsylvania Autoanticorps monoclonaux humains contre adamts13 et leurs utilisations
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
KR20180122397A (ko) * 2016-03-11 2018-11-12 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도

Also Published As

Publication number Publication date
JP7128801B2 (ja) 2022-08-31
MX2019000514A (es) 2019-07-12
KR102577551B1 (ko) 2023-09-11
SG11201900200XA (en) 2019-02-27
US20190292254A1 (en) 2019-09-26
IL264161A (en) 2019-02-28
US20210277100A1 (en) 2021-09-09
WO2018013939A1 (fr) 2018-01-18
EP3484499A4 (fr) 2020-05-13
AU2017294772B2 (en) 2024-05-02
KR20190034560A (ko) 2019-04-02
AU2017294772A1 (en) 2019-01-31
JP2019524094A (ja) 2019-09-05
CA3030862A1 (fr) 2018-01-18
CN110049773A (zh) 2019-07-23
EP3484499A1 (fr) 2019-05-22
IL264161B1 (en) 2025-02-01
BR112019000621A2 (pt) 2019-04-24
JP2022153406A (ja) 2022-10-12

Similar Documents

Publication Publication Date Title
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3423089A4 (fr) Anticorps anti-tigit
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA43814A (fr) Anticorps anti-gitr, méthodes et utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
EP3400239A4 (fr) Anticorps tétravalents contre psgl-1 et utilisations de ces derniers
MA49133A (fr) Anticorps agonistes anti-btla et leurs utilisations
MA47019A (fr) Agents, utilisations et procédés
EP3368567A4 (fr) Anticorps anti-dkk2 humanisés et leurs utilisations